Philips posts lower Q4 sales but maintains robust income

2021 11 30 16 08 9693 Philips Rsna 2021 400

The Diagnosis & Treatment business was a highlight for Philips in fourth-quarter financial results. The division, which includes the company's medical imaging activities, posted stable revenues while other Philips business declined.

For the period, the Diagnosis & Treatment division posted sales of 2.508 billion euros, flat after adjusting for currency changes compared with the year before. Revenues in the company's Connected Care business fell 32% after currency adjustment, while the Personal Health division dropped 3%.

The company said that the Diagnosis & Treatment business saw double-digit growth in Image-Guided Therapy during the fourth quarter.

For the entire company, Philips posted fourth-quarter sales of 4.944 billion euros, which represented a decrease of 10% after currency adjustment and about 350 million euros lower than what it anticipated. The company attributed the decrease to supply chain challenges.

For the full year, the Diagnosis & Treatment division saw an increase in revenues of 8% after currency adjustment, and an adjusted earnings before interest, taxes, and amortization (EBITA) margin of 12.4%.

Page 1 of 549
Next Page